First Trust NYSE Arca Biotechnology Index Fund Rating $178.24 +5.25 (+3.03%) As of 01/21/2025 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatings First Trust NYSE Arca Biotechnology Index Fund Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FBT Aggregate RatingModerate Buy 2.64Holdings in FBT have an aggregate rating of Moderate Buy based on 524 analyst ratings issued in the past year covering 29 companies (96.1% of the portfolio).FBT Aggregate Price Target$178.24High Prediction$178.24Average Prediction$178.24Low Prediction$178.24Holdings in FBT have an aggregate price target of $178.24 and a range of $178.24 to $178.24 covering 29 companies (96.1% of the portfolio).FBT Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust NYSE Arca Biotechnology Index Fund Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 29 FBT Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.40%ITCIIntra-Cellular Therapies$126.50+0.2%3.8263 of 5 stars2.67$100.31 -20.7%153.67%CORTCorcept Therapeutics$61.11+10.5%4.1058 of 5 stars3.00$65.25 6.8%53.54%MTDMettler-Toledo International$1,325.38+2.3%4.1556 of 5 stars2.11$1,351.25 2.0%9Positive News3.52%WATWaters$413.63+2.4%4.4073 of 5 stars2.33$384.71 -7.0%153.47%ALKSAlkermes$30.10+2.1%4.5391 of 5 stars2.64$36.00 19.6%113.44%HALOHalozyme Therapeutics$55.94+2.1%4.2897 of 5 stars2.60$60.89 8.8%10Short Interest ↑3.43%ALNYAlnylam Pharmaceuticals$264.99+7.6%4.3797 of 5 stars2.72$298.61 12.7%25Analyst ForecastGap Up3.43%AMGNAmgen$274.81+1.0%4.891 of 5 stars2.44$314.91 14.6%27Positive News3.43%RGENRepligen$167.92+4.6%3.7258 of 5 stars2.62$185.20 10.3%133.41%VRTXVertex Pharmaceuticals$427.89+1.4%4.302 of 5 stars2.52$490.38 14.6%31Positive News3.38%GILDGilead Sciences$92.96+1.2%4.567 of 5 stars2.70$97.96 5.4%27Analyst RevisionPositive News3.38%INCYIncyte$73.47+2.1%4.7858 of 5 stars2.35$76.29 3.8%203.37%ACADACADIA Pharmaceuticals$17.89+1.8%3.9071 of 5 stars2.59$25.25 41.1%173.37%NBIXNeurocrine Biosciences$145.88+1.8%4.8812 of 5 stars2.83$164.81 13.0%23News Coverage3.33%EXELExelixis$36.43+0.6%4.6943 of 5 stars2.53$35.50 -2.6%193.31%ILMNIllumina$141.31+3.4%4.5149 of 5 stars2.70$165.63 17.2%203.26%UTHRUnited Therapeutics$367.97+2.5%4.926 of 5 stars2.73$378.36 2.8%15Positive NewsHigh Trading Volume3.24%REGNRegeneron Pharmaceuticals$687.80+0.9%4.6173 of 5 stars2.65$1,015.38 47.6%233.23%VCYTVeracyte$43.60+7.4%3.9734 of 5 stars2.67$41.13 -5.7%9News CoveragePositive News3.23%ARGXargenx$647.39+1.1%2.3342 of 5 stars2.86$658.39 1.7%22Gap Up3.13%BIIBBiogen$140.98+0.3%4.7341 of 5 stars2.43$230.00 63.1%283.13%SRPTSarepta Therapeutics$116.79-1.0%4.9629 of 5 stars2.91$178.71 53.0%223.11%GMABGenmab A/S$21.80+4.8%4.42 of 5 stars2.67$45.20 107.3%9Gap Up3.10%BRKRBruker$60.07+5.6%4.9082 of 5 stars2.58$74.45 23.9%123.03%EXASExact Sciences$54.26+4.9%4.819 of 5 stars2.94$72.94 34.4%18News Coverage3.02%BMRNBioMarin Pharmaceutical$62.53+1.6%4.9979 of 5 stars2.74$94.20 50.6%233.02%BNTXBioNTech$117.25+4.8%1.7725 of 5 stars2.88$142.72 21.7%173.00%NTRANatera$167.46+5.7%2.41 of 5 stars3.00$160.63 -4.1%162.67%MRNAModerna$35.89+5.4%4.7869 of 5 stars2.13$75.58 110.6%23Gap Up This page (NYSEARCA:FBT) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust NYSE Arca Biotechnology Index Fund Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust NYSE Arca Biotechnology Index Fund With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.